An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVENTM in Subjects With Cancer Who Also Have Impaired Renal Function



Status:Recruiting
Conditions:Cancer, Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/1/2014
Start Date:August 2011
Contact:Eisai Medical Services
Phone:1-888-422-4743

Use our guide to learn which trials are right for you!

An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVENTM in Subjects With Cancer Who Also Have Impaired Renal Function

This is an open-label non-randomized study in subjects with advanced or metastatic solid
tumors who are no longer responding to available therapy. HALAVEN will be administered to
subjects on Days 1 and 8 of a 21-day cycle.


Inclusion Criteria:

- Histologically or cytologically confirmed advanced solid tumors that have progressed
following standard therapy or for which no standard therapy exists (including surgery
or radiation therapy).

- Renal function must fall into one of the following categories:

- Normal function - creatinine clearance greater than or equal to 80 mL/min.

- Moderate impairment - creatinine clearance >30 to 50 mL/min.

- Severe impairment - creatinine clearance 15 to less than 30 mL/min.

- Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the
upper limit of normal (ULN) and alkaline phosphatase (ALP), alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) less than or equal to 3 times the ULN (in
the case of liver metastasis less than or equal to 5 times ULN). In the case ALP >3
times the ULN (in the absence of liver metastasis) or >5 times the ULN (in the
presence of liver metastasis), and the subject is also known to have bone metastasis,
the liver specific ALP must be separated from the total and used to assess the liver
function instead of the total ALP.

Exclusion Criteria:

- Subjects with mild renal impairment (creatinine clearance greater than 50 to less
than 80 mL/min).

- Subjects with end stage renal disease (creatinine clearance less than 15 mL/min or on
dialysis).

- Subjects with a hypersensitivity to halichondrin B and/or halichondrin B chemical
derivatives.

- Subjects with prior participation in an HALAVEN clinical study, even if not
previously assigned to HALAVEN treatment.

- Radiation therapy encompassing >30 % of bone marrow.

- Subjects with organ allografts requiring immunosuppression.
We found this trial at
8
sites
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
St.Louis, MO
Click here to add this to my saved trials